In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (12/2009)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.

You may also be interested in...



Theraclion SAS

Paris-based Theraclion SAS has developed a non-surgical approach to treating hyperparathyroidism. The company's TH-One technology employs an externally applied converging beam of high-intensity focused ultrasound to create a rapid temperature rise in the extremely small parathyroid glands. Each pulse of energy produces a small lesion of coagulation, leading to destruction of the parathyroids.

SpineAlign Medical Inc.

Patients with osteoporotic vertebral compression fractures now have another alternative to vertebroplasty or kyphoplasty. The SpineAlign system from SpineAlign Medical Inc. uses a combination of cement and a permanent implant to elevate the vertebral endplates in parallel. In addition, the expandable metal device is composed of nitinol threaded at the end, so that a pedicle screw can be attached and locked into the system for a sturdy construct.

Pico-Tesla Magnetic Therapies LLC

Pico-Tesla Magnetic Therapies LLC's [noninvasive neuromodulation platform uses low levels of electromagnetic field to improve signs and symptoms of Parkinson's disease. The field strengths used by the company's Resonator device are in orders of magnitude below those utilized in MRI scanners or transcranial magnetic stimulators and thus should present no risk to patients.

Related Content

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel